Solid Biosciences (SLDB) Amortizatization of Intangibles (2017 - 2026)
Solid Biosciences (SLDB) reported Amortizatization of Intangibles of $619000.0 for Q1 2026, up 98.4% on a YoY basis from $312000.0 in Q1 2025, and down 17.14% sequentially from $747000.0 in Q4 2025.
Solid Biosciences (SLDB) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Solid Biosciences (SLDB) has 10 years of Amortizatization of Intangibles data on file, last reported at $619000.0 in Q1 2026.
- For the quarter ending Q1 2026, Amortizatization of Intangibles rose 98.4% year-over-year to $619000.0; the trailing twelve-month figure through Mar 2026 stood at $2.2 million (down 35.17% YoY), and the FY2025 full-year result was $1.9 million, down 47.83% from the prior year.
- Amortizatization of Intangibles fell to $619000.0 in Q1 2026, from $747000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $1.2 million in Q3 2024 to a low of -$371000.0 in Q1 2022.
- A 5-year average of $485882.4 and a median of $488000.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- Across the five-year window, Amortizatization of Intangibles jumped 5688.24% in 2023 and tumbled 72.93% in 2025, its largest moves.
- Tracing SLDB's Amortizatization of Intangibles over 5 years: stood at $276000.0 in 2022, then soared by 317.03% to $1.2 million in 2023, then slumped by 30.23% to $803000.0 in 2024, then fell by 6.97% to $747000.0 in 2025, then dropped by 17.14% to $619000.0 in 2026.
- Business Quant data shows SLDB's Amortizatization of Intangibles at $619000.0 in Q1 2026, $747000.0 in Q4 2025, and $327000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 3.22 Mn |
| 10 | Solid Biosciences | 871.35 Mn | 871.35 Mn | - | 619,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 619,000.00 |
| Mar 31, 2026 | 619,000.00 |
| Dec 31, 2025 | 747,000.00 |
| Dec 31, 2025 | 747,000.00 |
| Sep 30, 2025 | 327,000.00 |
| Sep 30, 2025 | 327,000.00 |
| Jun 30, 2025 | 488,000.00 |
| Jun 30, 2025 | 488,000.00 |
| Mar 31, 2025 | 312,000.00 |
| Mar 31, 2025 | 312,000.00 |
| Dec 31, 2024 | 803,000.00 |
| Dec 31, 2024 | 803,000.00 |
| Sep 30, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Jun 30, 2024 | 1.04 Mn |
| Mar 31, 2024 | 540,000.00 |
| Mar 31, 2024 | 540,000.00 |
| Dec 31, 2023 | 1.15 Mn |
| Dec 31, 2023 | 1.15 Mn |